Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer
To access this article, please choose from the options below
PII: S0305-7372(99)90150-0
doi:10.1053/ctrv.1999.0150
PII: S0305-7372(99)90150-0
doi:10.1053/ctrv.1999.0150